Floatz logo

Recombinant Human EGF-rP64K

Chronic Obstructive Pulmonary Disease

Roswell Park Cancer InstituteEarly Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Chronic Obstructive Pulmonary Disease cohort.

Asset / SponsorPhaseRating
Liraglutide
Claus Bogh Juhl
Phase 4BB
Roflumilast
Prince of Songkla University
Phase 3BB
Ciprofloxacin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
.ALPHA.-1 PROTEASE INHIBITOR
Takeda
Phase 4BB
Tazobactam
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Human EGF-rP64K is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
lung cancerDormant
BB
Indicative ·
65 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →